Waters Corp (WAT) 2026 Q2 法說會逐字稿

內容摘要

  1. 摘要
    • Q2 2026 營收達 16.45 億美元,超越指引高標,Organic revenue YoY 成長 7%(constant currency 9%),Biosciences & Diagnostic Solutions YoY 成長 4%;調整後 EPS 為 3.05 美元,亦達指引高標
    • 上修 2026 全年營收與 EPS 指引:Organic constant currency revenue 成長預估調升至 7-9%,Biosciences & Diagnostic Solutions 營收預估上調 1,000 萬美元,全年調整後 EPS 指引提升至 14.45-14.65 美元
    • 市場反應未明確揭露,但管理層強調執行力與成長動能優於同業,並持續推進收購後整合與新產品上市
  2. 成長動能 & 風險
    • 成長動能:
      • 收購 BD Biosciences & Diagnostic Solutions 首完整季度即帶動中高個位數成長,180 天整合計畫成效顯著
      • 創新產品推動成長:新一代質譜儀(cyclic IMS 20、Xevo MRTP 10)、生物分離新產品、BACTEC FXI 血液培養系統等上市
      • GLP-1 檢測需求強勁,Q2 相關業務成長超過 40%,涵蓋美洲、歐洲、印度、中國等多地
      • 中國市場復甦,Pharma 客戶雙位數成長,生技、CDMO、CRO 活動回溫,帶動區域加速成長
      • 美國製藥產能回流(reshoring)帶來 2027-2030 年間明確增量機會,Waters 在相關客戶市佔高,預期能受益
    • 風險:
      • 中國 Biosciences 及 Diagnostic Solutions 仍受 DRG 政策與產品本地化進度影響,短期內成長受壓
      • 外匯(美元升值)對營收與 EPS 產生逆風,部分抵銷營運改善效益
      • 工業與化學分析市場需求波動較大,客戶訂單具周期性與宏觀敏感度
  3. 核心 KPI / 事業群
    • Analytical Sciences:營收 6.69 億美元,YoY +7%(constant currency +9%);Pharma YoY +11%,Academic & Government +11%,Industrial +1%
    • Biosciences:營收 3.68 億美元,YoY +3%;Flow Clinical YoY +8%,Flow Research YoY -2%(但趨勢改善)
    • Advanced Diagnostics:營收 5.21 億美元,YoY +7%;其中 Diagnostic Solutions 4.49 億美元,YoY +5%,Clinical business unit YoY +15%
    • Material Sciences:營收 8,700 萬美元,YoY +6%(constant currency +8%)
    • GLP-1 檢測:Q2 成長超過 40%,印度業務幾乎翻倍,美洲/歐洲分別超過 30%/36% 成長
  4. 財務預測
    • 2026 全年 Organic constant currency revenue 成長預估 7-9%,Organic reported revenue 33.7-34.31 億美元
    • Biosciences & Diagnostic Solutions 2026 年營收預估 30.45 億美元(上調 1,000 萬美元)
    • 全年調整後 EBIT margin 預估 28.2%,全年調整後 EPS 指引 14.45-14.65 美元(YoY +10-12%)
    • 2026 年度預計實現 7,500 萬美元成本節省,年底 run rate 達 2 億美元
  5. 法人 Q&A
    • Q: BD Life Sciences(收購業務)中期成長展望?6% 以上成長是否可持續?
      A: 管理層表示對執行力非常滿意,預期 2026 下半年及 2027 年進一步受惠於領導層變動、產品上市、定價與中國本地化,預計年底成長率可達 6% 以上,為 2027 年奠定良好基礎。
    • Q: EPS 指引僅小幅上調,是否過於保守?有無包含關稅退稅假設?
      A: EPS 上調主要受美元升值抵銷營運改善,Q4 工作天數減少也帶來 1-1.5% 成長逆風,關稅退稅對損益影響中性。
    • Q: BD 業務定價提升進度?何時能達到 150bps 目標?
      A: Q2 已實現 90bps 價格貢獻,全年目標維持 150bps,已聘請專家推動 reagent rental 合約合規,預期有助於加速新產品滲透與價格提升。
    • Q: 美國製藥產能回流(reshoring)對成長的貢獻與時程?
      A: 短中期(2027-2030)為明確增量機會,Waters 在相關客戶市佔高,預期能維持或提升市佔,具高度可見性,但暫不量化具體貢獻。
    • Q: 中國微生物診斷市場展望?如何維持成長?
      A: Q2 表現優於預期,已推動產品本地化、領導層與執行力調整,Q4 將有本地化 FX/FXI 產品上市,對未來成長具信心。

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Welcome to the Waters Corporation second-quarter 2026 financial results conference call. (Operator Instructions) This call is being recorded. If anyone has objections, please disconnect at this time. It is now my pleasure to turn the call over to Mr. Caspar Tudor, Head of Investor Relations.

    歡迎參加沃特世公司(Waters Corporation)2026 年第二季財務業績電話會議。(接線員指示) 本通話將被錄音。如有任何異議,請此刻中斷連線。現在我很榮幸將電話交給投資人關係主管 Caspar Tudor 先生。

  • Please go ahead, sir.

    先生,請開始。

  • Caspar Tudor - Head - Investor Relations

    Caspar Tudor - Head - Investor Relations

  • Thank you, Leila, and good morning, everyone. Welcome to Waters Corporation second quarter earnings call. Joining me today are Dr. Udit Batra, our President and Chief Executive Officer; and Amol Chaubal, our Senior Vice President and Chief Financial Officer. Before we begin, I will cover the cautionary language.

    謝謝你,Leila,各位早安。歡迎參加沃特世公司第二季財報電話會議。今天與我一同出席的有:我們的總裁兼執行長 Udit Batra 博士,以及資深副總裁兼財務長 Amol Chaubal。在開始之前,我將先說明前瞻性聲明的警語。

  • In this conference call, we will make various forward-looking statements regarding future events or future financial performance of the company. including the financial and operational impact of Waters, Biosciences and Diagnostic Solutions businesses acquired from Becton, Dickinson and Company or BD. We will provide guidance regarding possible future results and commentary on potential market and business conditions that may impact Waters Corporation over the third quarter of 2026 and full year 2026.

    在本次電話會議中,我們將就公司未來事件或未來財務表現發表各項前瞻性聲明,包括自 Becton, Dickinson and Company(BD)收購之 Waters、Biosciences 與 Diagnostic Solutions 業務對財務與營運的影響。我們將提供可能的未來業績指引,並評論可能影響沃特世公司 2026 年第三季及 2026 全年之市場與業務狀況。

  • These statements are only our present expectations and are subject to risks and uncertainties. Please see the risk factors included within our Form 10-K, our Form 10-Qs or other SEC filings and the cautionary language included in this morning's earnings release. During today's call, we will refer to certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are attached to our earnings release and in the appendix of the slide presentation accompanying today's call. Unless stated otherwise, all organic revenue growth rates are presented on a constant currency basis and are in comparison to the second quarter of 2025.

    上述聲明僅代表我們目前的預期,並可能受到風險與不確定性影響。請參閱我們的 Form 10-K、Form 10-Q 或其他向美國證券交易委員會(SEC)提交之文件中的風險因素,以及今早新聞稿中的警語說明。在今天的電話會議中,我們將提及若干非 GAAP 財務衡量指標。與最直接可比之 GAAP 指標的調節表已附於我們的財報新聞稿,並收錄於今日電話會議隨附簡報的附錄中。除非另有說明,所有有機營收成長率均以固定匯率基礎呈現,並與 2025 年第二季相比。

  • For acquired business revenue unless stated otherwise, all growth rates are presented on an as-reported basis, covering the current period in comparison to the revenue as reported by BD for the prior year comparable period that predates Water's ownership. Finally, we do not intend to update our guidance, predictions or projections, except as part of a regularly scheduled earnings release or as otherwise required by law. On today's call, Udit will begin with our key messages and business highlights. Amol will then review our financial results and updated guidance. After that, we will open up the lines for questions.

    就收購業務營收而言,除非另有說明,所有成長率均以申報口徑(as-reported basis)呈現,涵蓋本期並與 BD 在上一年度可比期間(即沃特世取得所有權之前)所申報之營收相比。最後,除非作為例行財報發布的一部分或法律另有要求,我們無意更新我們的指引、預測或推估。在今天的電話會議中,Udit 將先分享我們的關鍵訊息與業務亮點。接著 Amol 將回顧我們的財務結果與更新後的指引。之後我們將開放提問。

  • I'll now turn the call over to Udit.

    現在我把電話交給 Udit。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Thank you, Caspar, and good morning, everyone. We delivered an excellent second quarter executing ahead of guidance across all four divisions as a powerful new era of growth extends across Waters. We sustained industry-leading results at our legacy businesses, fueled by strong commercial performance and pioneering innovation in our product portfolio. While recovery in our end markets broadened into previously lagging customer segments and further augment our growth. We've built outstanding momentum in our newly acquired businesses in their first full quarter under Waters' leadership driving an acceleration to mid-single-digit growth as the control actions from our 180-day plan have quickly taken hold and are already reshaping their trajectory.

    謝謝你,Caspar,各位早安。我們在第二季交出極佳成績,四大事業部皆超越指引,沃特世強勁的新成長時代正全面展開。我們在既有核心業務持續維持業界領先的成果,受惠於強勁的商業執行力,以及產品組合中具開創性的創新。同時,我們終端市場的復甦擴大至先前落後的客戶族群,進一步增強我們的成長動能。在新收購業務於沃特世領導下的第一個完整季度,我們建立了卓越動能;隨著 180 天計畫的管控措施迅速到位並已開始重塑其發展軌跡,成長加速至中個位數。

  • . We also took further decisive steps towards building our new platform for sustained long-term growth, executing flawlessly on our revenue synergies and cost actions as we enter our next phase of growth. Over the last few months, I've visited many sites and many customers. Our teams are executing with rigor and speed and advancing our value creation road map faster than we expected. I want to thank them for their dedication before we turn to the results.

    .我們也採取更果斷的進一步措施,打造可支撐長期持續成長的新平台;在進入下一階段成長之際,我們在營收協同效益與成本行動上執行無懈可擊。過去幾個月,我走訪了許多據點與客戶。我們的團隊以嚴謹與速度落實執行,推進價值創造藍圖的速度超出我們預期。在進入業績說明之前,我要感謝他們的投入與奉獻。

  • In the second quarter, total company as reported revenue was USD1.645 billion, comprising of $828 million of organic revenue and $817 million of Waters Bioscience and Diagnostic Solutions. Organic revenue grew 7% as reported and 9% in constant currency, exceeding the high end of our currency guidance range by approximately 100 basis points, with orders again outpacing sales. Underlying growth was double digits as this performance absorbed a 1% headwind from pull forward in last year's second quarter.

    第二季,公司合併申報營收為 16.45 億美元,其中包含 8.28 億美元的有機營收,以及 8.17 億美元的沃特世 Bioscience 與 Diagnostic Solutions 營收。有機營收申報成長 7%,以固定匯率計成長 9%,較我們匯率指引區間上緣高出約 100 個基點,且訂單再次超過銷售。在吸收去年第二季提前拉貨所造成的 1% 逆風後,基礎成長仍達雙位數。

  • Bioscience and Diagnostic Solutions revenue also exceeded our guidance. Revenue outpaced guidance by $15 million and grew 4% on a reported basis versus the prior year comparable period. With these businesses under our leadership for the entirety of the quarter, we achieved a 400 basis point improvement in reported growth versus last quarter's flat full quarter growth rate. Our strong momentum and disciplined cost management offset adverse foreign exchange translation as the US dollar strengthened since our last call. Adjusted EPS grew 3% to $3.05, landing at the high end of our guidance range.

    Bioscience 與 Diagnostic Solutions 的營收也超越我們的指引。營收較指引高出 1,500 萬美元,並較去年可比期間以申報口徑成長 4%。在這些業務整季皆由我們領導的情況下,我們的申報成長率較上一季整季持平的成長率提升 400 個基點。我們強勁的動能與嚴謹的成本管理,抵銷了自上次電話會議以來美元走強所帶來的不利外匯換算影響。調整後每股盈餘(Adjusted EPS)成長 3% 至 3.05 美元,落在指引區間上緣。

  • Let me now cover these drivers of strength in more detail. Beginning with the Analytical Sciences division, growth was 7% as reported and [9%] in constant currency with instruments up 8%, chemistry up 10% and service up 9%. We grew double digits in both our pharma and academic and government end markets for the second consecutive quarter, driven by improving market conditions, strong commercial execution and the merits of new product innovation in our industry-leading portfolio. Thanks to continued cross-divisional collaboration, we placed approximately $10 million of mass spec instruments into pharma DMPK settings in the quarter as early revenue synergies continued to build.

    接下來我將更詳細說明這些強勁表現的驅動因素。先從分析科學(Analytical Sciences)事業部開始,申報成長 7%,以固定匯率計為 [9%];其中儀器成長 8%、化學品成長 10%、服務成長 9%。在市場狀況改善、強勁的商業執行,以及我們業界領先產品組合中新產品創新的優勢帶動下,我們在製藥以及學術與政府終端市場連續第二季達成雙位數成長。受惠於跨事業部的持續協作,本季我們在製藥 DMPK 應用場景中部署約 1,000 萬美元的質譜儀器,早期營收協同效益持續累積。

  • In Analytical Sciences, we have continued to build our innovation leadership position with a number of new product launches in recent months. At ASMS, we launched two new high-resolution mass spec products, the cyclic IMS 20 and the Xevo MRTP 10. Both delivered step change improvements in sensitivity as the cyclic IMS P20 raises the in structural and spatial omics, while the Xevo MRTP not only sets a new standard for speed and throughput in multiomics but does so in a highly efficient benchtop format, which is unique in high-resolution mass spec. In bio separations, we launched our BioResolve, peptide and GTS resolve lipid columns.

    在分析科學領域,我們近幾個月透過多項新產品上市,持續鞏固創新領導地位。在 ASMS 上,我們推出兩款新的高解析度質譜產品:cyclic IMS 20 與 Xevo MRTP 10。兩者皆在靈敏度上帶來躍升式改善;cyclic IMS P20 提升於結構與空間組學(omics)方面的能力,而 Xevo MRTP 不僅在多組學(multiomics)的速度與通量上樹立新標準,並以高度高效的桌上型(benchtop)形式實現,這在高解析度質譜領域相當獨特。在生物分離(bio separations)方面,我們推出 BioResolve、peptide 以及 GTS resolve lipid 色譜柱。

  • Both delivered industry-first particle optimization, reliably separating structurally and chemically similar impurities in GLP-1 peptides insulin and nanoparticles with twice the resolving power and sensitivity of competing products.

    兩者皆提供業界首創的顆粒最佳化,可可靠分離在結構與化學性質上相近的雜質,適用於 GLP-1 胜肽、胰島素與奈米粒子,且其分離度與靈敏度為競品的兩倍。

  • The Biosciences division grew 3% as reported, improving 400 basis points from the 1% full quarter decline in the first quarter, excluding China, which represented a 2% headwind to growth, the division grew 5%. The growth acceleration was primarily driven by Flow Clinical, which grew 8% on a reported basis, improving versus both the 7% partial growth rate and flat full quarter growth rate in the first quarter.

    Biosciences 事業部申報成長 3%,較第一季整季下滑 1% 改善 400 個基點;若排除中國(對成長造成 2% 逆風),該事業部成長 5%。成長加速主要由 Flow Clinical 帶動,其申報成長 8%,較第一季 7% 的部分期間成長率以及整季持平的成長率皆有所改善。

  • Performance was led by mid-teens growth outside of China, reflecting sharpened execution, greater commercial activity from new KPIs and early benefits of our incremental pricing initiatives. In Flow Research, Reagents returned to positive growth in the quarter, reflecting an improvement in customer activity levels.

    表現主要由中國以外市場的中十位數成長所帶動,反映更聚焦的執行、更高的商業活動(源自新的 KPI),以及我們額外定價措施的早期效益。在 Flow Research 方面,Reagents 本季恢復正成長,反映客戶活動水準改善。

  • At the divisional level, advanced diagnostics grew 7% on a reported basis even with China remaining a notable drag on growth due to ongoing DRG headwinds. Within the division, the acquired Diagnostic Solutions business grew 5% as reported, accelerating versus the 1% full quarter growth rate in Q1.

    在事業部層級,即使中國因持續的 DRG 逆風而仍對成長造成明顯拖累,先進診斷(advanced diagnostics)仍以申報口徑成長 7%。在該事業部內,收購的 Diagnostic Solutions 業務申報成長 5%,較第一季整季 1% 的成長率加速。

  • Excluding China, growth was 7%. In microbiology, we grew mid-single digits as we drove a relentless focus on execution, improved utilization of black tech bottles and began to enact list price increases across the portfolio. In molecular diagnostics and point of care, we grew high single digits, driven by strong placements in molecular diagnostics related to HPV testing on BD core.

    不含中國,成長為7%。在微生物學方面,隨著我們持續專注於執行、提升黑色科技瓶的使用率,並開始在整體產品組合推動調漲牌價,我們實現了中個位數成長。在分子診斷與定點照護方面,我們在BD核心平台上與HPV檢測相關的分子診斷強勁裝機帶動下,實現了高個位數成長。

  • Also within the division, the organic clinical business unit grew 15% as reported and 14% in constant currency, led by double-digit strength in the Americas and Europe. We recently launched the Xevo TQ Absolute XR IVD mass spec, the industry's most sensitive and robust clinical IVD system. It delivers 5x greater sensitivity and a sixfold increase in robustness for critical applications, including women's health, cancer assessment and toxicology, further expanding our technological advantage in the IVD market.

    同樣在該事業部內,有機臨床業務單元按報告口徑成長15%,按固定匯率成長14%,主要由美洲與歐洲的兩位數強勁表現帶動。我們近期推出Xevo TQ Absolute XR IVD質譜儀,為業界最靈敏且最強健的臨床IVD系統。其可提供5倍更高的靈敏度與6倍的強健性提升,適用於女性健康、癌症評估與毒理學等關鍵應用,進一步擴大我們在IVD市場的技術優勢。

  • The Materials Science division returned to high single-digit growth in constant currency. Strength was driven by electronic research testing, semiconductor and data center applications together with advanced materials testing in aerospace and defense applications. Our leadership in battery safety testing was recently expanded with the launch of our on-cell differential scanning calrimeter, which represents a significant advancement in battery thermal analysis simultaneously capturing thermal evolved gas and electrochemical data.

    材料科學事業部按固定匯率計算恢復至高個位數成長。成長動能來自電子研究測試、半導體與資料中心應用,以及航太與國防應用中的先進材料測試。我們近期推出電芯級差示掃描量熱儀(on-cell differential scanning calrimeter),擴大了我們在電池安全測試的領導地位;該產品代表電池熱分析的重大進展,可同時擷取熱釋放氣體與電化學數據。

  • Our organic growth results reflect a successful strategy that has played out over the past several years across commercial execution, new product innovation and entering faster-growing adjacencies. Having delivered in each of these areas, we have achieved our promise of high single-digit growth over the past 7 quarters. This is the long-term trajectory strategy was built to deliver and legacy Waters is now structurally a durable high single-digit growth business.

    我們的有機成長結果反映出一項成功策略,該策略在過去數年已在商業執行、新產品創新以及切入成長更快的相鄰市場等方面逐步落地。在上述各領域均交出成果後,我們已兌現過去7個季度維持高個位數成長的承諾。這正是該長期軌跡策略所要達成的成果,而傳統Waters如今在結構上已成為一個具韌性的高個位數成長業務。

  • So far, in 2026, our organic business has accelerated further, marked by 10% constant currency growth for the first half of the year. These industry-leading results reflect outstanding growth momentum now amplified as our end markets have continued to strengthen and early cross-selling revenue synergies have continued to build.

    截至目前,2026年我們的有機業務進一步加速,上半年按固定匯率成長10%。這些領先業界的成果反映出卓越的成長動能;隨著終端市場持續走強,以及早期交叉銷售帶來的營收協同效益持續累積,該動能正被進一步放大。

  • Looking within analytical sciences, the best of this performance is clear. In pharma, we've grown double digits this year, driven by robust CapEx spending trends across large pharma, contract organizations and generics. This has been augmented by our idiosyncratic growth drivers tied to GLP-1 testing, India and biologics, which includes bioseparations and bioanalytical characterization.

    從分析科學內部來看,這項表現中最亮眼的部分十分清楚。在製藥領域,我們今年實現兩位數成長,主要受大型藥廠、委外機構與學名藥廠的資本支出(CapEx)趨勢強勁所帶動。此外,我們亦受惠於自身特有的成長驅動因素,包括與GLP-1檢測、印度與生物製劑相關的需求,其中涵蓋生物分離與生物分析特性鑑定。

  • Notably though, US biotech and CROs have moved over the past two quarters, adding a new layer of demand to the recovery. At the same time, we have seen a strong recovery from our pharma customers in China with double-digit growth in the first half of the year, accelerating versus last year's 6% growth rate and making China now accretive to our growth again. This reflects excellent commercial execution alongside a resurgence in biotech, CDMOs and CRO activity as Chinese companies buoyed by the commercial success of their research and out-licensing model attract investment and reinvest into R&D.

    值得注意的是,美國生技公司與CRO在過去兩個季度出現回升,為復甦增添了新一層需求。同時,我們也看到中國製藥客戶強勁復甦,上半年實現兩位數成長,較去年6%的成長率進一步加速,使中國再次對我們的成長形成正向貢獻。這反映出優異的商業執行力,以及生技、CDMO與CRO活動的回溫;中國企業在研究成果與對外授權(out-licensing)模式的商業成功帶動下吸引投資,並再投入研發。

  • Beyond the near-term recovery, this points to a broader structural tailwind. As Chinese discovery output continues to scale, and the out-licensing model matures, we are well indexed to the team since molecules developed on Waters platforms transfer cleanly into western development and regulatory pathways. In our nonpharma end market, we have seen growth rate acceleration led by double-digit growth in academic and government. Performance was broad-based across geographies, including a return to positive growth in the Americas in the second quarter.

    除了短期復甦之外,這也指向更廣泛的結構性順風。隨著中國新藥發現產出持續擴大、對外授權模式日趨成熟,我們的布局契合度很高,因為在Waters平台上開發的分子可順利銜接至西方的開發與法規審批路徑。在非製藥終端市場方面,我們看到成長率加速,其中以學術與政府領域的兩位數成長為主導。各地區表現普遍強勁,包括美洲在第二季重回正成長。

  • In Industrial, which grew low single digits in the Analytical Science division, PFAS has remained a source of strength and has grown double digits this year. Our growth is led by food analysis, which has now surpassed environmental analysis as our largest PFAS application for the first time. The broad strength of our customers bodes well for the instrument replacement cycle, where we remain firmly in the middle innings with a significant run rate still ahead.

    在分析科學事業部中,工業領域呈低個位數成長;其中PFAS仍是主要強項來源,且今年實現兩位數成長。我們的成長由食品分析帶動;食品分析如今首次超越環境分析,成為我們最大的PFAS應用領域。客戶端的廣泛強勁態勢,對儀器汰換週期形成良好支撐;我們仍明確處於該週期的中段,後續仍有可觀的成長動能。

  • Despite recent strong growth trends, our instrument revenue has grown only 2.5% on an organic constant currency CAGR basis versus 2019, well below the 5% long-term historical growth rate from 2009 to 2019. This gap reflects the multiphase recovery that has emerged since the middle of 2024, which has elongated the replacement cycle beyond what has historically been a two to three-year typical duration.

    儘管近期成長趨勢強勁,但相較於2019年,我們的儀器營收按有機、固定匯率口徑的年複合成長率(CAGR)僅成長2.5%,明顯低於2009年至2019年長期歷史5%的成長率。此差距反映出自2024年年中以來出現的多階段復甦,使汰換週期被拉長,超出過往通常為兩到三年的典型期間。

  • Beyond the replacement cycle, pharma reshoring also represents an increasingly well-defined incremental growth opportunity for Waters in the years ahead. We've been tracking 76 expansion sites linked to US pharma investment announcements.

    除汰換週期之外,製藥回流(reshoring)亦代表Waters未來數年愈發清晰的增量成長機會。我們一直在追蹤與美國製藥投資公告相關的76個擴建據點。

  • Roughly half are now under active construction, representing approximately $100 billion in CapEx spend, confirming that at least a portion of these commitments are beginning to translate into real capital deployment on the ground. Weighing the focus, modality and analytical intensity of each site, we expect instrument outfitting to drive a revenue tailwind for our analytical sciences division over the next three to five years.

    其中約有一半已進入積極施工階段,代表約1,000億美元的資本支出(CapEx),證實至少部分承諾正開始轉化為實際的在地資本投入。綜合考量各據點的重點、治療/技術模態以及分析強度後,我們預期未來三到五年,儀器配置將為我們的分析科學事業部帶來營收順風。

  • As sites move into -- from construction to equipping, we are well positioned to capture a disproportionate share of the resulting demand given that approximately 70% of the track sites are linked to customer accounts where Waters hold a high market share. We are already seeing funnel activity tied to a number of these sites. In our acquired businesses, we have continued to drive positive impact from our 180-day growth revitalization plan with each of our three near-term rapid execution initiatives already contributing to our results.

    隨著據點從施工階段進入—由施工轉為設備配置階段,我們具備良好條件以取得不成比例的需求份額;原因在於約70%的追蹤據點與Waters市占率較高的客戶帳戶相關。我們已看到與其中多個據點相關的商機漏斗活動。在我們併購的業務中,我們持續透過180天成長振興計畫帶來正向影響;三項短期快速執行的倡議均已開始對業績做出貢獻。

  • Our first priority, driving urgency accountability and transparency, the commercial discipline and KPI focus we quickly established at the close of the transaction is now embedded and compounding across the acquired businesses. As a result, funnel conversion rates are rising, field activity has stepped up materially and the outbound momentum we built in Q1 has rested further through the second quarter.

    我們的第一項優先事項是推動緊迫感、問責與透明度;在交易完成時我們迅速建立的商業紀律與KPI聚焦,如今已深植於併購業務中並持續累積成效。因此,商機漏斗轉換率正在上升,前線活動顯著增加,而我們在第一季建立的外拓動能在第二季進一步延續。

  • On our second priority, pine excellence and contract compliance -- we have made fast moves to embed the same discipline at Biosciences and Diagnostic Solutions that we established at legacy Waters. We've hired -- we have hired dedicated pricing directors for each division structured our 2026 and 2027 pricing actions to drive incremental price realization and have already enacted list price increases across parts of the acquired portfolio, achieving 90 basis points of net price realization in the second quarter alone.

    在第二項優先事項—定價卓越與合約遵循—方面,我們已快速採取行動,將在傳統Waters建立的同等紀律導入至生物科學與診斷解決方案業務。我們已為各事業部聘任專責定價總監,規劃2026與2027年的定價行動以推動額外的價格落地,並已在併購產品組合的部分品項實施牌價調漲,僅第二季就達成90個基點的淨價格實現。

  • We are well on our way towards our goal of achieving 150 basis points of price contribution in the acquired businesses. On Reagent rental compliance, a review of global Diagnostic Solutions contracts remains active. The mediation efforts are underway across the approximately 700 US contracts already identified as out of compliance. To supplement this effort, we have brought in a dedicated operational leader with deep industry experience who has managed similar programs before.

    我們正穩步朝向在併購業務中達成150個基點價格貢獻的目標邁進。在試劑租賃(reagent rental)合規方面,對診斷解決方案全球合約的審查仍在進行中。針對已識別約700份不合規的美國合約,調解工作正在展開。為補強此項工作,我們已引進一位具深厚產業經驗的專責營運主管,其過去曾管理過類似計畫。

  • On our third priority, regaining share in flow research, we've made meaningful progress across several fronts. In China, we have significantly improved the speed and efficiency of export license approvals generating twice the number of license approvals in the second quarter versus the first full quarter and helping to reverse the share loss dynamics that constrained prior performance.

    在第三項優先事項—奪回流式研究(flow research)市占—方面,我們在多個面向已取得實質進展。在中國,我們大幅提升出口許可核准的速度與效率,使第二季取得的許可核准數量較第一個完整季度增加一倍,並有助於扭轉先前限制表現的市占流失態勢。

  • Results have been tangible. China Flow Research, which declined 30% in the full first quarter improved to mid-single-digit decline in the second quarter, a swing of approximately 25 percentage points. Meanwhile, our localized manufacturing program for flow instruments is well underway and expected to begin contributing to growth in the fourth quarter.

    成果已相當明顯。中國流式研究在第一季整季下滑30%,第二季改善至中個位數下滑,約提升25個百分點。同時,我們針對流式儀器的在地化製造計畫正穩步推進,預期將於第四季開始對成長做出貢獻。

  • With a successful transformation behind him, [Ching Lee], our General Manager for the -- as China business has now taken on the added responsibility of revitalizing growth for Biosciences in China. Ching and his team are moving decisively to implement new commercial rigor and accountability while sharpening our focus on the pharma market given the recent in Chinese biotechs, CDMO and CRO activity.

    在成功完成轉型之後,[Ching Lee](我們中國業務的總經理)如今也承擔起在中國重振生物科學(Biosciences)成長的額外責任。鑑於近期中國生技公司、CDMO 與 CRO 活動的變化,Ching 與其團隊正果斷推動更嚴謹的商業紀律與問責機制,同時在藥廠市場上進一步聚焦。

  • Across our geographies, we also have an attractive share recapture and instrument replacement opportunity in flow cytometry with the fax discover A7 cell analyzer, which we unveiled at SITO and is set to launch on September 15.

    在各個地區,我們也在流式細胞儀領域看到具吸引力的市占回收與儀器汰換機會,來自 fax discover A7 細胞分析儀;我們已在 SITO 發表,並預計於 9 月 15 日上市。

  • The A7 fills a key gap in our portfolio while setting a new benchmark in spectrum flow cytometry, bringing IVD-level standardization and reproducibility to a spectral analyzer for the first time. Leveraging automation and self calibration, it also enables workflows to easily transition between instruments and users, representing meaningful innovation for our customers.

    A7 彌補了我們產品組合中的關鍵缺口,同時在光譜流式細胞儀方面樹立新的標竿,首次將 IVD 等級的標準化與可重現性帶入光譜分析儀。透過自動化與自我校準,它也讓工作流程能在不同儀器與使用者之間輕鬆轉換,為客戶帶來具實質意義的創新。

  • In Advanced Diagnostics, BACTEC FXI, our next-generation blood culture system recently received FDA 510(k) clearance, enabling US commercialization as we scale the launch globally in microbiology. With placements now beginning in Japan and Europe, we are excited about the instrument replacement potential that BACTEC FXI holds, particularly given the early customer feedback we've received.

    在先進診斷(Advanced Diagnostics)方面,我們的下一代血液培養系統 BACTEC FXI 近期已取得 FDA 510(k) 核准,使我們得以在美國商業化,同時在微生物學領域推動全球擴大上市。隨著日本與歐洲開始裝機,我們對 BACTEC FXI 所具備的儀器汰換潛力感到振奮,尤其是考量到我們收到的早期客戶回饋。

  • BACTEC FXI is a groundbreaking system. It detects bloodstream infections up to three hours faster than competing systems offers 2 to 3 times the input capacity and provides customers with meaningful productivity advantages and labor cost savings. It leads across each of the critical attributes that matter to our customers and is now the flagship product of the industry.

    BACTEC FXI 是一套突破性的系統。它偵測血流感染的速度最多可比競品系統快 3 小時,提供 2 到 3 倍的進樣容量,並為客戶帶來顯著的生產力優勢與人力成本節省。在客戶最重視的各項關鍵屬性上,它都居於領先地位,現已成為業界的旗艦產品。

  • Depending on daily volume, customers can extend up to 10 days of annualized time savings versus the prior generation systems. And we have already -- we are already seeing benefits in practice as one of our early adopter sites in Japan, reported an 80% reduction in hands on time after switching to FXI.

    依每日檢測量而定,客戶相較於上一代系統,每年可延伸節省最多達 10 天(年化)的時間。而且我們已在實務上看到效益:日本的一個早期採用據點在改用 FXI 後,回報其手動操作時間降低了 80%。

  • With these notable new advantages the funnel is building and the commercial opportunity ahead is substantial. With over 12,000 aged BACTEC systems past due for replacement, we have a large, well-defined installed base that we intend to convert. Much like how Alliance iS has given -- has driven durable replacement revenue in HPLC, we expect BACTEC FXI to be a multiyear growth engine in microbiology. Beyond our near-term execution, we're also making early trials into high-growth adjacency in biosciences that we believe will become increasingly important over time.

    憑藉這些顯著的新優勢,商機漏斗正在建立,未來的商業機會相當可觀。目前有超過 12,000 台老舊的 BACTEC 系統已逾期需要汰換,我們擁有龐大且界定清楚的既有裝機基礎,並計畫加以轉換。就如同 Alliance iS 在 HPLC 領域帶來——並推動了持續性的汰換營收一樣,我們預期 BACTEC FXI 將成為微生物學領域的多年期成長引擎。除了近期的執行重點之外,我們也正開始在生物科學的高成長相鄰領域進行早期試點,我們相信這些領域將隨時間推移變得愈來愈重要。

  • As AI models continue to become more capable of designing -- as AI models grow more capable of designing new antibodies, proteins and genetic constructs, the limiting factor is shifting from competition to biology. Generating large-scale immune and disease data sets, these models depend on and require physical biology testing. Flow cytometry is well positioned as an enabling hardware layer given its unique ability to capture high-parameter single-cell resolution at real-time clinical scale.

    隨著 AI 模型在設計新抗體、蛋白質與基因構築方面的能力持續提升,限制因素正從運算競爭轉向生物學本身。為了生成大規模免疫與疾病資料集,這些模型仰賴並需要實體的生物測試。流式細胞術具備獨特能力,可在即時臨床規模下捕捉高參數的單細胞解析度,因此非常適合作為賦能的硬體層。

  • Our recently announced strategic partnership with IMU Biosciences is an early proof point of our important role supporting next-generation immune profiling and AI-enabled precision medicine in clinical diagnostic applications.

    我們近期宣布與 IMU Biosciences 的策略合作夥伴關係,是我們在臨床診斷應用中支持下一代免疫分型與 AI 驅動精準醫療的重要角色之早期佐證。

  • IMU has raised over $50 million to date as it accelerates its work to decode the immune system and transform how we understand, diagnose and treat disease. Together, we're scaling a precision immunology platform for population-wide immune mapping and disease characterization in what is expected to become the world's largest immune data set.

    IMU 迄今已募資超過 5,000 萬美元,正加速其解碼免疫系統的工作,並改變我們理解、診斷與治療疾病的方式。我們將共同擴大一個精準免疫學平台,用於全人群的免疫圖譜繪製與疾病特徵刻畫;該平台預期將成為全球最大的免疫資料集。

  • Turning now to our cost actions and updated guidance. We have completed our planned cost actions for 2026 as our teams flawlessly implemented our restructuring plan with speed and discipline. In operations, we have unlocked spend control, driven by early direct procurement savings, restructured field operations in service and begun optimizing manufacturing and supply chain costs.

    接下來談我們的成本行動與更新後的財測指引。我們已完成 2026 年規劃的成本行動;各團隊以速度與紀律完美落實重整計畫。在營運方面,我們已強化支出控管,這得益於早期的直接採購節省;同時重整服務的前線營運,並開始優化製造與供應鏈成本。

  • Across functions, we've made significant progress on cost efficiency by optimizing spans and layers, eliminating redundancy and achieving a leaner centralized cost structure. These actions also carry an important strategic dimension beyond the cost benefit.

    在各職能面,我們透過優化管理幅度與層級、消除重複並建立更精實的集中式成本結構,在成本效率上取得顯著進展。這些行動除了成本效益之外,也具有重要的策略面向。

  • They sharpen the structure of acquired businesses, reduce bureaucracy and accelerate information flow. They also support the direction of accountability and commercial focus that will make them structurally stronger over time. Together, these actions reflect $75 million in cumulative cost savings expected in 2026, supporting solid margin progression in the second half of the year.

    它們使併購業務的組織架構更清晰、降低官僚作風並加速資訊流動。同時也支持問責與商業聚焦的方向,讓組織結構隨時間推移更為強健。綜合而言,這些行動預計在 2026 年帶來累計 7,500 萬美元的成本節省,支撐下半年穩健的利潤率提升。

  • They also represent approximately $200 million of expected run rate savings, placing us ahead of schedule that we had already laid out. They put us in a strong position to hit our margin expansion goals and drive mid-teens adjusted EPS growth over the next several years.

    它們也代表預期約 2 億美元的年化(run rate)節省,使我們進度超前於先前已提出的時程。這讓我們處於有利位置,可達成利潤率擴張目標,並在未來數年推動調整後 EPS 的中十位數成長。

  • To close, let me frame our 2026 guidance and give an update on our value creation road map. With momentum building across our portfolio and end markets, we are raising every component of our full year 2026 guidance, which Amol will detail shortly.

    最後,讓我為 2026 年財測指引做個框架說明,並更新我們的價值創造路線圖。隨著我們的產品組合與終端市場動能持續增強,我們上調 2026 全年財測指引的每一個組成項目;Amol 稍後將進一步說明。

  • Our growth strategy has delivered and legacy Waters is now a sustainable high single-digit grower. For the acquired businesses, we are running ahead of our goals for the first half of the year and are positioned for growth acceleration in the second half of the year. The 180-day plan has progressed rapidly.

    我們的成長策略已交出成果,傳統 Waters 業務如今已成為可持續的高個位數成長者。就併購業務而言,我們上半年表現已超越目標,並已就位以在下半年加速成長。180 天計畫進展迅速。

  • Revenue synergies are already contributing to our results, and we are launching category-defining new products. This positions us to build further momentum in the second half where cross-selling synergies are joined by instrument replacement, service plan attachment and digital channel adoption.

    營收協同效應已開始貢獻業績,我們也正推出具類別定義性的新品。這使我們得以在下半年進一步累積動能:交叉銷售協同效應將與儀器汰換、服務方案附加率提升以及數位通路採用共同發力。

  • In total, we remain well on track to deliver $50 million of revenue synergies this year. In Biosciences, we will benefit from China localization and new commercial leadership in the second half, positioning us well with the local biotech and CDMO community and driving faster growth. While the launch of fax discovered A7 coincides nicely with a strengthening biotech and academic end market in the US.

    整體而言,我們仍穩健朝今年實現 5,000 萬美元營收協同效應的目標前進。在生物科學方面,下半年我們將受惠於中國在地化與新的商業領導團隊,使我們能更好地與當地生技與 CDMO 社群對接並推動更快成長。同時,fax discovered A7 的上市時點也與美國生技與學術終端市場的回溫相互呼應。

  • In Advanced Diagnostics, we delivered high single-digit growth despite a 2% China DRG headwind that rolls into the baseline in the fourth quarter with BACTEC FXI and on Clarity, HPV at home testing solution now launching, the setup for the second half is excellent.

    在先進診斷方面,儘管受到中國 DRG 2% 的逆風影響(該影響將在第四季納入基期),我們仍實現高個位數成長;隨著 BACTEC FXI 以及 Clarity(HPV 居家檢測解決方案)開始上市,下半年的布局非常理想。

  • As end market conditions continue to strengthen and our growth strategy compounds, Waters is better positioned today than at any point in recent history with a broad portfolio, a larger installed base and the cleanest set of growth catalysts we've ever had.

    隨著終端市場狀況持續改善、我們的成長策略持續複利累積,Waters 今日的定位較近期任何時點都更佳:擁有更廣的產品組合、更大的既有裝機基礎,以及我們歷來最清晰的一組成長催化劑。

  • With that, I will now turn the call over to Amol to cover our financial results and guidance in more detail.

    接下來,我將把電話會議交給 Amol,由他更詳細說明我們的財務結果與財測指引。

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Thank you, Udit, and good morning, everyone. In the second quarter of 2026, we delivered total company as reported revenue of $1.645 billion. Organic revenue was $828 million, growing 7% as reported and 9% in constant currency. Versus our guidance, constant currency sales were 100 basis points above the high end of the guidance range, while foreign exchange translation was 150 basis points. Biosciences and Diagnostic Solutions generated $870 million of revenue, representing 4% reported growth versus the prior year comparable period, led by 6% growth outside of China.

    謝謝你,Udit,各位早安。在 2026 年第二季,我們實現全公司(依報告口徑)營收 16.45 億美元。有機營收為 8.28 億美元,依報告口徑成長 7%,以固定匯率計成長 9%。相較於我們的指引,固定匯率銷售額高於指引區間上緣 100 個基點,而外匯換算影響為 150 個基點。生物科學與診斷解決方案合計營收 8.70 億美元,較去年同期(可比期間)依報告口徑成長 4%,其中中國以外地區成長 6% 為主要帶動因素。

  • . By geography, as reported revenue was $690 million in Americas, $505 million in Europe and $450 million in Asia. Total company adjusted gross margin came in line with our expectations at 54%, reflecting an anticipated sequential step down as our ownership of the acquired businesses normalized to a full quarter versus a partial quarter in the last period. Total company adjusted operating margin was also consistent with our expectations at 25%. Our tax rate was 15.6%, and net interest expense was $55 million with adjusted EPS of $3.05 landing at the high end of our guidance range.

    .按地理區域劃分,如報告口徑營收為:美洲 6.90 億美元、歐洲 5.05 億美元、亞洲 4.50 億美元。公司整體調整後毛利率為 54%,符合我們的預期,反映出如預期般的環比下滑,原因在於我們對所收購業務的持股在本期已正常化為完整一季,而上一期僅為部分季度。公司整體調整後營業利益率亦與我們的預期一致,為 25%。我們的稅率為 15.6%,淨利息費用為 5,500 萬美元,調整後每股盈餘(EPS)為 3.05 美元,落在我們指引區間的高端。

  • On a GAAP basis, we reported a diluted loss per share of $1.39, reflecting acquisition-related purchase accounting charges, including amortization of acquired intangibles and inventory step-up as is typical following a transaction of this care. Free cash flow for the quarter was $202 million after approximately $21 million in severance payments, $27 million of integration cost payments and given timing of net cash settlement. At the end of June, the net cash settlement due to orders from BD was $157 million.

    按 GAAP 口徑,我們報告稀釋後每股虧損 1.39 美元,反映了與收購相關的購買會計費用,包括收購無形資產攤銷及存貨增值(step-up),這在此類交易完成後屬常見情況。本季自由現金流為 2.02 億美元,已扣除約 2,100 萬美元的資遣費支付、2,700 萬美元的整合成本支付,並考量淨現金結算的時間差。截至 6 月底,因 BD 訂單所致的應付淨現金結算金額為 1.57 億美元。

  • Turning to our results by operating segment. The Analytical Sciences division delivered as reported revenue of $669 million, up 7% as reported and 9% in constant currency. In constant currency, instruments grew 8% and chemistry grew 10% and service grew 9%.

    接著看各營運事業部的表現。分析科學(Analytical Sciences)事業部如報告口徑營收為 6.69 億美元,如報告口徑成長 7%,以固定匯率計成長 9%。以固定匯率計,儀器成長 8%,化學品成長 10%,服務成長 9%。

  • By end market, Pharma grew 11%, while non-pharma grew 4% as academic and government grew 11% and industrial grew 1%. Within pharma, strength was driven by a robust replacement activity, our idiosyncratic growth drivers and further traction in pharma DMPK clinical settings. We also saw further improvement in market conditions with stronger US biotech and CRO spending, adding a new layer of demand to the recovery.

    按終端市場劃分,製藥(Pharma)成長 11%,非製藥成長 4%,其中學術與政府成長 11%,工業成長 1%。在製藥領域,成長動能來自強勁的汰換需求、我們特有的成長驅動因素,以及在製藥 DMPK 臨床場景中的進一步滲透。我們也看到市場環境進一步改善,美國生技與 CRO 支出更為強勁,為復甦增添了新的需求層次。

  • Growth was led by the US, China and the rest of Asia, each up double digits or better. Within academic and government, strength was driven by mid-teens growth in Europe, double-digit growth in Asia and 6% growth in the Americas. Demand remains strong for our revitalized mass spectrometry portfolio in discovery applications, including for the Xevo MRT, which is seeing strong customer traction. We also saw an emerged contribution in ANG from semiconductor research.

    成長主要由美國、中國及亞洲其他地區帶動,三者皆達到或超過雙位數成長。在學術與政府領域,成長動能來自歐洲約中十位數成長、亞洲雙位數成長,以及美洲 6% 成長。我們重新振興的質譜產品組合在探索(discovery)應用中的需求仍然強勁,包括 Xevo MRT,正獲得客戶強勁採用。我們也看到 ANG 來自半導體研究的新增貢獻。

  • Within Industrial, continued strength in food and environmental, led by double-digit growth in PFAS applications was partially offset by softness in chemical analysis, where customer ordering pattern can be lumpy and more macro sensitive. The Biosciences division delivered as reported revenue of $368 million, representing 3% reported growth versus the prior year comparable period and a 400 basis point acceleration in year year-over-year growth versus the full first quarter rates.

    在工業領域,食品與環境相關需求持續強勁,其中 PFAS 應用帶動雙位數成長;但化學分析需求偏弱部分抵銷了上述成長,該領域客戶下單模式可能較不均勻,且對總體環境更為敏感。生物科學(Biosciences)事業部如報告口徑營收為 3.68 億美元,較去年同期如報告口徑成長 3%,且相較第一季整體年增率水準加速 400 個基點。

  • Flow Clinical grew 8% on strong commercial execution, pricing, and improving end market conditions. Flow research declined 2% with the trajectory improving through the quarter as the regions returned to growth. In Flow Clinical, we grew mid-teens outside of China, while China declined 20% due to ongoing DRG constraints and lack of localized product portfolio, which we are in the process of addressing.

    流式臨床(Flow Clinical)在強勁的商業執行、定價以及終端市場狀況改善的帶動下成長 8%。流式研究(Flow Research)下滑 2%,但季度內走勢逐步改善,因各地區恢復成長。在流式臨床方面,中國以外地區成長約中十位數,而中國因持續的 DRG 限制及缺乏在地化產品組合而下滑 20%,我們正著手改善。

  • In Flow Research, the return to positive growth for RUO Reagents reflects an improvement in execution, pricing and underlying customer activity levels as market conditions continue to strengthen. Our annual way of commercial actions tied to RUO share recovery also began to contribute such as improvement in China research instrument growth trends tied to export license approval volumes.

    在流式研究方面,RUO 試劑恢復正成長,反映出執行力、定價與客戶活動水準的改善,因市場環境持續轉強。我們與 RUO 市占回升相關的年度商業行動也開始帶來貢獻,例如與出口許可核准量相關的中國研究儀器成長趨勢改善。

  • The Advanced Diagnostics division comprised the formal BD Diagnostic Solutions business and the clinical business unit previously reported within Waters division. Total as reported revenue for the division was $521 million, representing 7% reported growth versus prior year comparable period. Within the division, Diagnostic Solutions were $449 million of as reported revenue, representing 5% growth in the quarter and also a 400 basis points acceleration in growth versus full first quarter trend.

    先進診斷(Advanced Diagnostics)事業部包含正式併入的 BD Diagnostic Solutions 業務,以及先前在 Waters 事業部內報告的臨床業務單元。該事業部如報告口徑總營收為 5.21 億美元,較去年同期如報告口徑成長 7%。在該事業部內,Diagnostic Solutions 如報告口徑營收為 4.49 億美元,本季成長 5%,且相較第一季整體趨勢加速 400 個基點。

  • The clinical business unit delivered $72 million of revenue, up 15% as reported and 14% in constant currency. In microbiology, reported revenue was $319 million, reflecting 4% growth driven by improved commercial execution and incremental pricing actions. Growth outside of China was 6%, while China declined 13%, which was better than expected.

    臨床業務單元營收為 7,200 萬美元,如報告口徑成長 15%,以固定匯率計成長 14%。在微生物學(microbiology)方面,如報告口徑營收為 3.19 億美元,成長 4%,主要由商業執行改善與額外的定價措施帶動。中國以外地區成長 6%,而中國下滑 13%,但表現優於預期。

  • In molecular diagnostics and point of care, reported revenue was $129 million, reflecting 9% growth in the quarter, driven by strong placements in HPV testing on our BD core platform. In the clinical business unit growth was led by double-digit strength in the Americas and Europe, with early commercial collaboration across advanced diagnostics also beginning to contribute.

    在分子診斷與定點照護(point of care)方面,如報告口徑營收為 1.29 億美元,本季成長 9%,主要由我們 BD 核心平台上的 HPV 檢測裝機量強勁所帶動。在臨床業務單元方面,成長由美洲與歐洲的雙位數強勁表現帶動,同時先進診斷領域的早期商業協作也開始貢獻。

  • The Material Sciences division delivered as reported revenue of $87 million in the quarter, representing an increase of 6% as reported and 8% in constant currency as spending trends improved across our range of applications, including aerospace and defense and electronics testing for semiconductors and data center applications.

    材料科學(Material Sciences)事業部本季如報告口徑營收為 8,700 萬美元,如報告口徑成長 6%,以固定匯率計成長 8%,因我們各項應用的支出趨勢改善,包括航太與國防,以及用於半導體與資料中心應用的電子測試。

  • Now I will share further commentary on our full year outlook and provide our third quarter guidance. Beginning with organic revenue, we have achieved excellent results so far in '26 as our sustained growth trajectory is being augmented by additional customer segments now returning to growth. With this strong momentum, we are raising our full year 2026 organic constant currency revenue growth guidance to 7% to 9%. Foreign exchange translation is now expected to be a headwind of approximately 60 basis points, resulting in 2026, organic reported revenue of $3.37 billion to $3.431 billion.

    接下來我將進一步說明我們的全年展望,並提供 2026 年第三季指引。先從有機營收來看,我們在 2026 年迄今取得了優異成果,持續的成長軌跡正因更多客戶細分市場恢復成長而獲得加乘。在此強勁動能下,我們將 2026 年全年有機固定匯率營收成長指引上調至 7% 至 9%。外匯換算目前預期將帶來約 60 個基點的不利影響,因此 2026 年有機如報告口徑營收預期為 33.70 億至 34.31 億美元。

  • Turn to our acquired businesses, we now expect Biosciences and diagnostic solutions to deliver approximately $3.045 billion of reported revenue in 2026, raising our prior guidance by $10 million, which reflects an underlying improvement of $25 million, offset by $15 million of FX. Together, total 2026 reported revenue is expected to be approximately $6.415 billion to $6.476 billion based on latest FX rates.

    再看我們收購的業務,我們目前預期 2026 年生物科學與 Diagnostic Solutions 將貢獻約 30.45 億美元的如報告口徑營收,較先前指引上調 1,000 萬美元;其中反映基本面改善 2,500 萬美元,但被 1,500 萬美元的外匯影響所抵銷。綜合而言,依最新匯率,2026 年總如報告口徑營收預期約為 64.15 億至 64.76 億美元。

  • Our full year adjusted EBIT margin is expected to be 28.2% in 2026, consistent with our prior expectations as foreign exchange translation is offset by the $20 million of overachievement from our 2026 cost actions. Net interest expense is now expected to be approximately $190 million and our full year tax rate is now expected to be approximately 15.5%.

    我們預期 2026 年全年調整後 EBIT 利潤率為 28.2%,與先前預期一致,因外匯換算影響將被我們 2026 年成本行動超額達成的 2,000 萬美元所抵銷。淨利息費用目前預期約為 1.90 億美元,全年稅率目前預期約為 15.5%。

  • Putting all this together, full year 2026 adjusted earnings per fully diluted share is now expected to be $14.45 to $14.65. This represents year-over-year growth of 10% to 12% and is 12% to 14% in constant currency. For the third quarter of 2026, we expect organic constant currency revenue growth to be in the range of 8% to 10%. And Including the effect of currency lesion, organic reported revenue is expected to be in the range of $850 million to $867 million.

    綜合以上因素,2026 年全年調整後完全稀釋每股盈餘目前預期為 14.45 至 14.65 美元。這代表年增 10% 至 12%,以固定匯率計為 12% 至 14%。對於 2026 年第三季,我們預期有機固定匯率營收成長介於 8% 至 10%。並且包含匯率換算影響後,有機如報告口徑營收預期介於 8.50 億至 8.67 億美元。

  • We expect revenue from Biosciences and Diagnostic Solutions to be approximately [$ 95 million] in the third quarter of 2026, in line with the typical sequential seasonality for these businesses.

    我們預期 2026 年第三季來自生物科學與 Diagnostic Solutions 的營收約為 [9,500 萬美元],符合這些業務典型的季節性環比變化。

  • Together, these results in total reported third quarter 2026 revenue of $1.745 billion to $1.762 billion. Third quarter adjusted earnings per fully diluted share is expected to be in the range of $3.95 to $4.05, which is 16% to 19% growth. Turning to our implied guidance assumptions during the second half of the year. At the midpoint, our organic revenue guidance prudently calls for a 3.6% quarter-over-quarter step-up between the second and the third quarter, below the seasonality patterns we've seen over the last two years. Additionally, it prudently implies a 12.8% step-up in the fourth quarter, which is also below recent seasonal patterns.

    綜合以上因素,第三季 2026 年合計申報營收預計為 17.45 億至 17.62 億美元。第三季經調整後完全稀釋每股盈餘預期介於 3.95 至 4.05 美元,代表 16% 至 19% 的成長。接著談談我們對下半年隱含的指引假設。以中位數來看,我們的有機營收指引在審慎假設下,第二季到第三季的季增幅為 3.6%,低於過去兩年我們觀察到的季節性模式。此外,該指引亦審慎地隱含第四季季增 12.8%,同樣低於近期的季節性模式。

  • In the overall P&L, our cost actions are expected to yield a $25 million adjusted operating income benefit in the third quarter and a $50 million benefit in the fourth quarter for a combined positive estimated P&L impact of approximately $75 million, underwriting the solid margin progression in the second half guidance.

    在整體損益表(P&L)方面,我們的成本行動預期將在第三季帶來 2,500 萬美元的經調整營業利益增益,並在第四季帶來 5,000 萬美元的增益,合計對損益表的正向估計影響約 7,500 萬美元,支撐下半年指引中穩健的利潤率改善。

  • With that, I will now hand it back to Caspar.

    接下來,我把時間交還給 Caspar。

  • Caspar Tudor - Head - Investor Relations

    Caspar Tudor - Head - Investor Relations

  • Thanks, Amol. That concludes our prepared remarks. We are now happy to open the lines and take your questions.

    謝謝,Amol。以上為我們事先準備的發言。現在我們很高興開放電話線並回答各位的提問。

  • Operator

    Operator

  • (Operator Instructions) Vijay Kumar, Evercore ISI.

    (接線員指示)Vijay Kumar,Evercore ISI。

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • Congrats on a nice print here. Udit, maybe a first one for you on BD Life Sciences, it likely grew north of a 5% constant currency this is well above deal model, right? We're like five months into the deal, we're doing north of 5%. This is despite China headwinds persisting before any contribution from new products like your BACTEC FXI and pricing actions. Like how should we think about BDLS in the medium term? Is this now like a north of 6% asset in your mind?

    恭喜這次交出漂亮的成績。Udit,先問你一題關於 BD Life Sciences:以固定匯率計,成長可能超過 5%,這明顯高於交易模型(deal model),對吧?我們大概才進入交易後第五個月,就做到超過 5%。而且這還是在中國逆風持續、且尚未納入像你們的 BACTEC FXI 等新產品貢獻與漲價措施之前。那我們該如何看待 BDLS 的中期表現?在你看來,這是否已經是個年增超過 6% 的資產?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Vijay, thanks for the question, and good morning to you. Look, first just setting the context, I am ecstatic about the execution that we're seeing from our teams in Life Science -- in BD Life Sciences and BD Biosciences and Diagnostics. It is A plus, right? And Water is an execution machine, but I wait this as A plus really fantastic mid-single-digit growth for the acquired businesses already. As we move into the second half of 2026 and into '27 enabled by leadership changes, strengthen execution, as you mentioned, across pricing, instrument replacement, digital commerce.

    Vijay,謝謝你的提問,也早安。首先先交代背景:我對我們生命科學團隊的執行力感到非常振奮——包括 BD Life Sciences 以及 BD Biosciences and Diagnostics。這是 A+ 等級,對吧?而 Water 是一台執行機器,但我仍然給這個表現 A+:被收購業務目前就已經達到非常出色的中個位數成長。隨著我們進入 2026 年下半年並延伸到 2027 年,在領導層調整、執行力強化的帶動下,正如你提到的,涵蓋定價、儀器汰換、數位商務等面向。

  • We have a fantastic operating with them, right? And for Bioscience, A7, FACSDiscover A7 is launching on September 15, in now a much improved biotech and academic funding environment.

    我們與他們的營運配合非常出色,對吧?而在 Bioscience 方面,A7、FACSDiscover A7 將於 9 月 15 日上市,且目前生技與學術研究資金環境已明顯改善。

  • In China, we've localized our portfolio and we have the full flow cytometry portfolio available in Q4. So that should bring some nice there. For diagnostic solutions, FXI has launched well in Japan and in Europe and now available in the US with the 510(k) approval, roughly 4,500 instruments in the US alone waiting for replacement.

    在中國,我們已將產品組合在地化,並且在第四季將提供完整的流式細胞儀產品組合。因此那邊應該會帶來不錯的助益。在診斷解決方案方面,FXI 在日本與歐洲上市表現良好,且現在已取得 510(k) 核准、在美國也可供應;僅美國就約有 4,500 台儀器等待汰換。

  • And in China in Q4, the DRG headwinds will be in the baseline. So if you put it all together, we expect to exit the year with 6% or better growth rate for the two businesses and that sets us up really well entering into 2027. So I could not be more pleased with the execution we are seeing.

    而在中國,第四季 DRG 的逆風將會納入基期。因此綜合來看,我們預期今年年底時,這兩項業務的成長率可達 6% 或更高,這也讓我們在進入 2027 年時具備非常好的起點。所以我對目前看到的執行表現再滿意不過。

  • Vijay Kumar - Equity Analyst

    Vijay Kumar - Equity Analyst

  • That's helpful, Udit. And Amol, maybe one for you. Organic revenues for raise your cost action estimates were raised, but EPS increase of $0.05 that just reflects the second quarter bit being carried forward, right? Are we being conservative here on the EPS fall through? And can you just clarify if any tariff refund assumptions were baked into this EPS?

    很有幫助,Udit。Amol,我也想問你一題。有機營收上調、成本行動的估計也上調,但 EPS 只增加 0.05 美元,這只是把第二季的部分延續到後面而已,對吧?我們在 EPS 的落袋(fall-through)上是否偏保守?另外也請你釐清:這個 EPS 指引是否已納入任何關稅退稅(tariff refund)的假設?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • There's a couple of things there, right? So look, I mean, between the organic sales raise and the higher cost actions, we get about $0.03 of EPS. But then about $0.25 of EPS are eaten up by stronger U.S. dollar. And that's why you sort of see $0.05 EPS raise for the full year.

    這裡有幾個點。首先,介於有機銷售上調與更高的成本行動之間,我們大約帶來 0.03 美元的 EPS。但約有 0.25 美元的 EPS 被更強勢的美元所侵蝕。因此你才會看到全年 EPS 只上調 0.05 美元。

  • Two, if you look at how the implied guidance for Q4 for the organic business, it is a like 4% constant currency growth. No doubt, we have about three less working days in Q4, but they will translate to about 1%, 1.5% headwind to growth.

    第二,如果你看第四季對有機業務的隱含指引,大約是固定匯率下 4% 的成長。毫無疑問,第四季大約少了三個工作天,但這會轉化為約 1% 到 1.5% 的成長逆風。

  • And I think where the business trajectory is at this point, we're quite confident that the business is performing really well and will relatively stay there. It's a prudent guide for Q4. and we see how it plays out in Q4 on that context. And then the last piece is on the tariff refund, right? I mean, as you know, from last year, we were the first ones out of the gate to rapidly neutralize the impact of tariffs in our P&L by early October, the P&L was neutralized.

    以目前業務動能來看,我們相當有信心業務表現非常好,且大致會維持在這個水準。因此這是一個對第四季審慎的指引;我們會在這個脈絡下觀察第四季的實際表現。最後一點是關於關稅退稅。如你所知,從去年開始,我們是第一批迅速在損益表中中和關稅影響的公司;到 10 月初,損益表的影響就已被中和。

  • So when the tariff refunds would come, we will also have to go back on some of the surcharges we've charged customers, right? So net-net, it will be net neutral.

    因此當關稅退稅到來時,我們也必須回頭撤回(或調整)先前向客戶收取的一些附加費,對吧?所以整體而言,淨額(net-net)會是中性。

  • Operator

    Operator

  • Evie Koslosky, Goldman Sachs.

    Evie Koslosky,高盛。

  • Elizabeth Koslosky - Analyst

    Elizabeth Koslosky - Analyst

  • So you mentioned you're starting to see pricing flow through on the BD business. Maybe walk us through how much of the guidance raise in the raise in the acquired business is related to pricing? And then how quickly we could ramp to the 150 basis points? And I guess anything you're hearing customers as you work through these implementations? .

    你提到開始看到 BD 業務的定價效益逐步反映。能否帶我們了解一下:這次上調指引中,被收購業務的上調有多少是與定價相關?另外,我們能多快拉升到 150 個基點?以及在推動這些落地執行時,你們從客戶端聽到什麼回饋嗎?.

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yes. So Q2, EV, we did 0.9% versus the traditional 0.5. 0.5 was embedded in our guide last time. So we are increasing to 0.9 for the remainder of the year. The goal and aspiration is still to get as quickly as possible to 150 basis points.

    是的。所以在第二季,Evie,我們做到 0.9%,相較於傳統的 0.5%;上次的指引中原本內含的是 0.5%。因此我們把今年剩餘期間的假設提高到 0.9%。目標與企圖仍然是盡快達到 150 個基點。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yes. I mean just to build on that EV for one second, you will also remember we talked about the reagent rental compliance. We have 700 accounts in the US that we've profiled segmented. We've hired an expert from outside who is actually used to renegotiating these contracts and getting benefit for the company. So we expect that to help not just improve pricing, but also accelerate the uptake of our new products in those customer segments. So very excited about what we're seeing on that front.

    是的。我再補充 Evie 一點:你也會記得我們談過試劑租賃(reagent rental)的合規性。我們在美國已針對 700 個帳戶完成輪廓分析並做了分群。我們從外部聘請了一位專家,他過去就擅長重新談判這類合約並為公司爭取效益。因此我們預期這不僅能改善定價,也能加速我們新產品在這些客群中的導入。所以我們對這方面看到的進展非常振奮。

  • Elizabeth Koslosky - Analyst

    Elizabeth Koslosky - Analyst

  • Okay. Great. And then I wanted to touch on some of your comments on reshoring. How much of this is incremental versus just kind of shifting geographies? And then should we expect this to be additive to your organic growth expectations or more of just kind of a shifting forward? And then anything you could provide in terms of timing of when you expect this to flow through?

    好的。很好。接著我想談談你們對回流生產(reshoring)的一些評論。其中有多少是增量(incremental),而不是只是地理位置的轉移?另外,我們應該預期這會對你們的有機成長預期帶來額外貢獻,還是比較像把需求提前(shifting forward)?以及在時程上,你們預期何時會開始反映出來?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Look, I mean, first, on incremental growth. Look, we've been growing 8% on average for the last seven quarters in what's been an up and down market for many of our peers, right? So we don't need reshoring to add on, but it is incremental in the short to medium term. Over the long term, it's probably left pocket, right pocket as you look at the global pill count. In the short term, by short term, I mean 2027 to '30.

    你看,我的意思是,首先談增量成長。你看,在過去七個季度裡,儘管對我們許多同業而言市場起起落落,我們平均仍成長了 8%,對吧?所以我們不需要靠回流生產(reshoring)來加碼,但在短到中期它確實是增量。長期來看,從全球藥丸數量(pill count)的角度看,可能只是左口袋換右口袋。短期而言,我所說的短期是指 2027 到 2030 年。

  • I mean, we have incredible visibility on customers who have broken ground. I mean we talked about 37 or so of them, there is another similar number that are planning to break ground there, we feel we have a very strong position. Roughly 70% of those customers are Waters accounts. So as they shift from one geography to the other, we expect to maintain our share or gain share. So really excited about that.

    我的意思是,對於已經動工的客戶,我們有極高的能見度。我們提到大約 37 家左右,另外還有差不多同樣數量的客戶正計畫動工,我們覺得我們的地位非常強。其中約 70% 的客戶是 Waters 的既有客戶。因此當他們從一個地理區域轉移到另一個地理區域時,我們預期能維持市占,甚至提升市占。所以對此真的很興奮。

  • Overall, the reshoring benefit, I mean, if you take just two things away from our prepared remarks and what I'm saying now, one, it's a concrete opportunity in -- from 2027 to 2030. And two, we are very well placed to capture the opportunity. I won't quantify at this stage, what we're going to see, and you'll see that coming through over the next few quarters. But very happy with the visibility and the position we have there.

    整體而言,回流生產帶來的效益——我的意思是,如果你只從我們事先準備的發言以及我現在說的內容帶走兩點:第一,這是一個具體的機會,時間落在 2027 到 2030 年。第二,我們非常有利於把握這個機會。我現階段不會量化我們將看到什麼,你會在接下來幾個季度看到逐步反映。但我們對於能見度以及我們在那裡的布局位置非常滿意。

  • Operator

    Operator

  • Tycho Peterson, Jefferies.

    Tycho Peterson,Jefferies。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Udit, I want to touch on some of the flow cytometry initiatives. Good to see the return of growth in clinical. Just on the research side, how much of the pressure do you think is just lingering headwinds on US academic and government and biotech versus other factors? You mentioned the China initiatives, but I'm just curious about some of the other initiatives to turn around the flow research business?

    Udit,我想談談一些流式細胞儀(flow cytometry)的計畫。很高興看到臨床端恢復成長。就研究端而言,你認為壓力有多少是來自美國學術界、政府以及生技領域仍在延續的逆風,相較於其他因素?你提到中國的計畫,但我也想了解,還有哪些其他計畫用來扭轉流式研究業務?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yes. It's a great question, Tycho. On the flow reagent side, that grew this quarter, so low single digits. The headwinds are largely based on the instrument side. Bulk of it is from China.

    是的。這是個很好的問題,Tycho。在流式試劑(flow reagent)方面,本季是成長的,大約是低個位數。逆風主要來自儀器端。其中大部分來自中國。

  • In fact, the US saw growth on the instrument side in Bioscience and we are seeing benefits of an improving academic and biotech market in the US for sure. And just to sort of complete the thought on China. In China, there are sort of independent variables that you need to keep in mind.

    事實上,美國在生物科學(Bioscience)儀器端是有成長的,而且我們確實看到美國學術與生技市場改善所帶來的效益。再把關於中國的想法補充完整。在中國,有幾個你需要記住的獨立變數。

  • One, we have a broader flow cytometry portfolio available starting Q4. We've sort of localized our portfolio the same playbook we ran for legacy analytical sciences. And two, from an execution standpoint, we've put the guy in charge who has driven really outsized growth in China for us for the last six, seven quarters and driven sort of double-digit growth in China for us for the Analytical Science business. This is Ching Lee.

    第一,從第四季開始,我們會提供更完整的流式細胞儀產品組合。我們已經把產品組合在地化,採用的是我們過去在傳統分析科學(legacy analytical sciences)所使用的同一套打法。第二,在執行面,我們讓一位主管負責,他在過去六、七個季度為我們在中國帶來非常突出的成長,並且推動分析科學業務在中國達到雙位數成長。他就是 Ching Lee。

  • So we feel very good about the setup for Biosciences. And as I said in prepared remarks and to an earlier question, we expect to exit here in BioScience north of 6%.

    所以我們對生物科學(Biosciences)的布局非常有信心。而且如同我在事先準備的發言以及對先前問題所說的,我們預期生物科學的年增率在退出時會高於 6%。

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • And just the only thing I would add is the S8 and A8 doing fantastic. But then there is the gap that will rapidly be addressed with the launch of A7 and that will take care of the ex China, any remaining headwind.

    我唯一想補充的是,S8 和 A8 表現非常出色。但其中的缺口會隨著 A7 的推出而迅速補上,這將解決中國以外(ex China)任何剩餘的逆風。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yes, fantastic. And on A7, what you need to keep in mind is this is down Waters is fair, right? It's an instrument design for high-volume use where you can transfer methods from one flow cytometer to another, one user to another. So feel very good about the product.

    是的,很棒。至於 A7,你需要記住的是,這是 Waters 的強項,對吧?它是一款為高通量使用而設計的儀器,你可以把方法在不同流式細胞儀之間、不同使用者之間進行轉移。所以我們對這個產品非常有信心。

  • Tycho Peterson - Analyst

    Tycho Peterson - Analyst

  • Okay. That's full. And then a follow-up on the guidance. Maybe just a little bit more color. I mean, you're raising BD by more than the beat obviously. How much of that's bioscience versus microbio versus molecular? And then on margins, you're maintaining the guide despite taking up cost synergies. I guess, how should we think about the underlying margin trajectory really thinking about '27 here is 100 basis points still on the table for next year? .

    好的。這很完整。接著追問一下財測指引。也許再多給一點顏色。我的意思是,你上調 BD 的幅度明顯高於超預期的幅度。其中有多少來自生物科學(bioscience),多少來自微生物(microbio),多少來自分子(molecular)?另外在毛利率/利潤率方面,你在提高成本綜效的同時仍維持指引。我想問,我們該如何看待底層的利潤率走勢?如果把目光放到 2027 年,明年仍有 100 個基點的改善空間嗎?.

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yes. So a couple of things there. So on the BD raise, we are raising the underlying by about $25 million, and then that's partially offset by strong US dollar by about 15%. So the net raises about $10 million.

    是的。這裡有幾點。關於 BD 的上調,我們把底層(underlying)上調了大約 2,500 萬美元,而強勢美元部分抵銷了其中約 15%。所以淨上調大約 1,000 萬美元。

  • It's relatively evenly spread between Flow versus Diagnostic Solutions and even within Diagnostic Solutions sort of evenly spread between molecular and micro and a little bit lopsided to clinical versus research on the biosciences side.

    這在流式(Flow)與診斷解決方案(Diagnostic Solutions)之間分布相對平均;而在診斷解決方案內部,分子(molecular)與微生物(micro)也大致平均;在生物科學端則是臨床相對多一些、研究相對少一些。

  • Then when you look at the margin, I mean, no doubt the $20 million of additional cost actions brought in 30 basis points of better margin. But because of the currency mix of our business, the stronger US dollar took away the 30 basis points on margin returning back to [28.2]. We're still ahead of our underwriting on margin, right? Because we kind of said we go from 27% to 32% over the course of five years, 100 basis points each year. So we're running ahead of the 28% for this year, and our outlook is 100 basis points a year.

    再看利潤率,毫無疑問,額外 2,000 萬美元的成本行動帶來了 30 個基點的利潤率改善。但由於我們業務的匯率組合,強勢美元又拿走了這 30 個基點,使利潤率回到[28.2]。我們的利潤率仍然領先於我們的承銷/規劃假設(underwriting),對吧?因為我們先前說過,五年內從 27% 提升到 32%,每年提升 100 個基點。所以今年我們的表現高於 28% 的目標,而我們的展望仍是每年 100 個基點。

  • Operator

    Operator

  • Subbu Nambi, Guggenheim.

    Subbu Nambi,Guggenheim。

  • Subbu Nambi - Equity Analyst

    Subbu Nambi - Equity Analyst

  • Our checks suggest that you've already implemented a change in how discounting is managed at BD in general. We've heard that even in flow cytometry and to some extent in microbiology. Where are you in the process of how BD manages discounting? How is this driving you towards your eventual pricing goals, meaning is this still early innings? And then lastly, as you make these changes, is there a risk that as you potentially require more approvals to discount, you become less nimble relative to competitors. How do you manage that?

    我們的調查顯示,你們似乎已經在 BD 整體上實施了折扣管理方式的變更。我們也聽說在流式細胞儀,甚至在某種程度上在微生物領域也是如此。你們在 BD 折扣管理流程的推進進度到哪裡了?這如何推動你們走向最終的定價目標——也就是說,這是否仍在早期階段?最後,當你們做這些改變時,是否存在風險:例如你們可能需要更多核准才能給折扣,導致相較競爭對手不夠靈活?你們如何管理?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yes. I think, Subbu, great question. Look, we've implemented this playbook on the legacy Water side, where we set up a deal desk -- in fact, from a bureaucracy standpoint, it reduces the bureaucracy. Everyone is clear on what the escalation is, sometimes the approvals even come to my desk. So the deal desk model is efficient. It's been adopted by both divisions now. We have a deal desk across every region, very clear escalation protocols that allows us to manage the discounting really well. If anything, it's faster.

    是的。我想,Subbu,這是個很好的問題。你看,我們已在傳統 Waters 端實施了這套打法:建立交易審核中心(deal desk)——事實上,從官僚流程的角度,它反而降低了官僚性。每個人都清楚升級(escalation)路徑是什麼,有時候核准甚至會送到我的桌上。所以 deal desk 模式是有效率的。現在兩個事業部都已採用。我們在每個區域都有 deal desk,並有非常清楚的升級規範,讓我們能把折扣管理得很好。如果有什麼差別,那就是更快。

  • And in terms of pace, I mean, it's just the beginning, right? So we've already seen 90 basis points in Q2, where implementation of the deal desk and the execution discipline gave us a lift from the historical 50 basis points to 90, we're well honor to get to the 150 basis points. And as I said, you should expect faster approvals as opposed to slower.

    至於推進速度,我的意思是,這才剛開始,對吧?我們在第二季已經看到 90 個基點:deal desk 的導入與執行紀律,讓我們從過去歷史的 50 個基點提升到 90 個基點;我們也很有信心能達到 150 個基點。而且如我所說,你應該預期核准會更快,而不是更慢。

  • Subbu Nambi - Equity Analyst

    Subbu Nambi - Equity Analyst

  • Fantastic. And recently, you had a competitor come out and adjust that outlook for China microbiology. Can you give us your latest thoughts on how you see growth potential in that market and the specific ways you expect to maintain your outlook in the region despite reform.

    太好了。而且最近,你們有一家競爭對手出來調整了對中國微生物業務的展望。你能否分享一下你們最新的看法:你們如何看待該市場的成長潛力,以及在改革之下你們預期將以哪些具體方式在該區域維持你們的展望?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yes. Look, I mean, first, I mean, if you take a step back on China as a whole on the Diagnostics side, it's mostly microbiology for us. It came in actually better this quarter than we had predicted. It grew -- it basically declined low teens as opposed to 30% that we had put into our models. So did better.

    是的。你看,我的意思是,首先,如果你把中國整體在診斷業務這一塊拉遠一點看,對我們來說主要就是微生物。本季實際表現比我們預測的要好。它的變化——基本上是下滑低十幾個百分點,而不是我們模型裡放的 30% 下滑。所以表現更好。

  • And then from a future perspective, we've implemented several changes in the country itself. We are localizing our FX portfolio. That should be available in Q4 in the country. We've made leadership changes, and we've made execution changes on the ground level. So we feel pretty good about where we sit on the microbiology business.

    然後從未來的角度來看,我們已在該國內部實施了幾項變更。我們正在把 FX 產品組合在地化。預計在該國第四季可供應。我們也做了領導層調整,並在第一線做了執行面的調整。因此我們對微生物業務目前的位置感到相當有信心。

  • And what is ahead of Waters and not just the industry ahead for Waters, not just the industry. So with the availability of FX and FXI that is locally made with the leadership changes, feel pretty good about what we want -- what we expect with China going forward.

    而且對 Waters 而言,接下來的情況——不只是整個產業,對 Waters 也是如此,不只是產業。因此,隨著在地製造的 FX 與 FXI 的供應,再加上領導層變動,我們對未來中國的表現——我們對中國未來的預期——感到相當不錯。

  • Operator

    Operator

  • Puneet Souda, Leerink.

    Puneet Souda,Leerink。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • Great. Thanks for the question here. Congrats on a great print here. Good to see the BD acceleration here with it. The first one is actually in Water instrumentation and GLP1 Pharma is clearly strong for you here. But just wanted to see how much contribution you saw from GLP-1s in the quarter? And how should we think about that trajectory going forward, both in the developed markets and in India as well. I just recall this being a major contributor that you had talked about at the prior Investor Day, so I wanted to get some color there.

    很好。謝謝讓我提問。恭喜這次交出很漂亮的成績。也很高興看到 BD 這邊的加速。第一個問題其實是在 Waters 儀器方面,而 GLP1 製藥對你們顯然很強勁。但我想了解本季 GLP-1 對你們的貢獻大概有多少?以及往後我們該如何看待這個趨勢,包含成熟市場以及印度。我記得你們在上一次投資人日提到這會是主要貢獻來源之一,所以想請你們多分享一些細節。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yes. Let me start and then let Amol add in. Look, GLP-1s, Puneet grew that part GLP-1 testing for part of the business grew over 40% this quarter. Broad-based growth across virtually every geography. Americas over 30%.

    是的。我先回答,然後讓 Amol 補充。你看,Puneet,GLP-1 這一塊——GLP-1 檢測相關的那部分業務——本季成長超過 40%。幾乎所有地區都呈現廣泛成長。美洲成長超過 30%。

  • Europe, over 36%. India almost doubling the business itself. So very broad-based. And also in China, where 1 of the leading contract manufacturers are supporting [Eli Lilly] in their contract manufacturing where we have a meaningful share. So very broad-based growth on GLP-1 testing.

    歐洲超過 36%。印度幾乎讓該業務本身翻倍。所以是非常廣泛的成長。另外在中國也一樣,其中一家領先的委託製造商正在為 [Eli Lilly] 提供委託製造支援,而我們在那裡有相當可觀的市占。因此 GLP-1 檢測呈現非常廣泛的成長。

  • And as you look ahead, I mean there are no signs of slowing down. The pipeline is very good. The funnel looks both on instruments as well as on the chemistry side. So really no slowdown on that front. In fact, moving ahead -- moving ahead of what we had promised on the GLP-1 testing contribution.

    而往前看,我的意思是,目前看不到放緩的跡象。研發管線非常好。不論是儀器端還是化學端,商機漏斗看起來都很強。所以在這方面真的沒有放緩。事實上,進展——進展已經超前於我們先前承諾的 GLP-1 檢測貢獻。

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yes. I mean, look, broadly, we had said the idiosyncratic growth drivers will all add up to about 200 basis points. And the GLP-1 contribution there was about 30 basis points. Clearly, GLP-1s are running well ahead of that.

    是的。我的意思是,整體來看,我們曾說過這些特定的成長驅動因素加總大約會帶來 200 個基點。其中 GLP-1 的貢獻大約是 30 個基點。很明顯,GLP-1 的表現遠遠超過這個水準。

  • Puneet Souda - Analyst

    Puneet Souda - Analyst

  • Got it. Got it. Great. And then on the BD side, I mean, with the 180-day plus plan, it seems that that's run its course. I mean, you're seeing strong results across the BD Enterprise which of the initiatives are more permanent run rate versus one-timers in the enterprise. I'm wondering how should we start to think about the sort of the annualized revenue contribution here in '27? How should we think about '27 with the BD raise here in '26?

    了解。了解。很好。接著在 BD 方面,我的意思是,隨著 180 天以上的計畫,看起來已經走完一輪。你們在 BD Enterprise 各方面都看到很強的成果;在這些措施中,哪些是較為永久、可形成常態化的 run rate,哪些是一次性的?我想問的是,我們該如何開始思考到 2027 年時這裡的年化營收貢獻?在 2026 年 BD 上修的情況下,我們該如何看待 2027 年?

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • There will be ample time to talk about 2027, Puneet. But I mean, all I can say is add it all up and we exit '26 north of 6%, and that's sort of very aggressive from what we had started with very positive from where we started with a minus 10% last year same time. So really happy with the execution. Our 180-day plan -- these are systemic improvements, right? So the first one is on the commercial execution.

    Puneet,談 2027 年還有很多時間。但我的意思是,我能說的是,把所有因素加總起來,我們在 2026 年結束時會高於 6%,相較於我們一開始的基準,這是非常積極的;而且相較於去年同期的負 10%,也是非常正向的改善。所以我們對執行成果非常滿意。我們的 180 天計畫——這些都是系統性的改善,對吧?第一項是在商業執行上。

  • And we expect that to now be embedded in the organization on funnel management, on pricing and the like. The second 1 is pricing and reagent compliance. I mean we -- as I mentioned earlier, already 90 basis points. We're well on our way to get to 150 basis points. And the Reagent rental compliance, I mean, we know the customers that have been delinquent -- we have value propositions for different segments and those will get implemented over time.

    我們預期這些做法現在會內嵌到組織中,包括漏斗管理、定價等等。第二項是定價與試劑合規。我的意思是——如我先前提到的,已經帶來 90 個基點。我們正順利朝 150 個基點邁進。至於試劑租賃(reagent rental)合規,我的意思是,我們知道哪些客戶有逾期——我們針對不同客群有不同的價值主張,這些會隨時間逐步落地。

  • And the third one was around China, right? I mean once we localize our portfolio in China, that's a gift that should keep giving plus we have one of our best GMs in the company, leading now Bioscience in addition to his Analytical Sciences Divisional responsibility. So those are systemic improvements that we expect to contribute going forward. And as you look ahead, remember, our revenue synergies were not just cross-selling of what we talked about earlier, which is $50 million for this year.

    第三項是圍繞中國,對吧?我的意思是,一旦我們把產品組合在中國在地化,這就像是一份會持續帶來效益的禮物;此外,我們也讓公司裡最優秀的總經理之一,除了原本負責分析科學事業部外,現在也領導生物科學。所以這些都是我們預期未來會持續貢獻的系統性改善。而往前看,請記得,我們的營收協同不只是我們先前談到的交叉銷售——也就是今年的 5,000 萬美元。

  • Total revenue synergies, including cross-selling in drug metabolism, but also cross-selling of LC-MS and diagnostics, instrument replacement, digital commerce service and pricing, all of those will augment to the growth already that you're seeing from the 180-day plan.

    整體營收協同還包括:在藥物代謝領域的交叉銷售,以及 LC-MS 與診斷的交叉銷售、儀器汰換、數位商務服務與定價;所有這些都會在你目前從 180 天計畫看到的成長之上,進一步增強成長動能。

  • So very excited about what we're seeing. I mean, the teams are collaborating really, really well. Couldn't have asked for better execution. As I mentioned earlier, I mean, Waters is a strong execution company, but this is A+ execution.

    所以我們對目前看到的情況非常振奮。我的意思是,團隊之間的協作真的非常、非常好。執行表現再好不過了。如我先前提到的,Waters 一向是執行力很強的公司,但這次是 A+ 等級的執行。

  • Operator

    Operator

  • Jack Meehan, Nephron Research.

    Jack Meehan,Nephron Research。

  • Jack Meehan - Equity Analyst

    Jack Meehan - Equity Analyst

  • First question, I wanted to follow up on Tyco's second question more around the cost actions, though. So you've built in $75 million for 2026 with a $200 million run rate, is that $50 million in 4Q a good starting point for thinking about what 2027 could look like? Or should -- or is there a different way we should think about kind of the building blocks in the next year on the cost synergy side?

    第一個問題,我想延續 Tyco 的第二個問題,但更聚焦在成本措施上。你們在 2026 年納入了 7,500 萬美元,且有 2 億美元的 run rate;那麼第四季的 5,000 萬美元是否可以作為思考 2027 年可能樣貌的一個良好起點?或者——或者我們應該用不同方式來看待明年在成本協同方面的組成要素(building blocks)?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yes. I mean great question, Jack. So the $50 million in Q4 is largely in hand because we've already taken these cost actions. People have been communicated, they have their debts, et cetera. And so that already puts us at a $200 million run rate.

    是的。這是個很好的問題,Jack。第四季的 5,000 萬美元大致上已經到手,因為我們已經採取了這些成本行動。人員已完成溝通,他們也已經安排好交接等等。因此這已經讓我們達到 2 億美元的 run rate。

  • And that covers a big portion of the scope we outlined. But I mean, as you can imagine, as we look at the business and optimize the business further, there are areas which we continue to look at, such as network consolidation at this point that takes typically time, looking at things such as how we manage inventory and that produces outcomes. So those things will come as we go through the years to come.

    而這涵蓋了我們所概述範圍中的很大一部分。但我的意思是,如你所想像的,當我們檢視業務並進一步優化時,仍有一些領域會持續評估,例如目前的網路整併(network consolidation)通常需要時間;以及像是我們如何管理庫存,這也會產生成效。所以這些會在未來幾年隨著我們推進而逐步實現。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Let me add on a bit, Jack, right? I mean, you'll remember our benchmark that we had shared from some previous deals was about 7.5% of total cost base. I mean, $200 million is 4%. We have a fair number of initiatives that we want to continue to -- continue to implement beyond the $200 million that we've already delivered. It's too early to add that on to 2027 and beyond. And we will have ample time to talk about it. But I think you think your question is the right one. I mean what else do we expect? There's more. I mean, there's no question about that.

    我再補充一點,Jack,對吧?我的意思是,你會記得我們先前在一些交易中分享過的基準,大約是總成本基礎的7.5%。我的意思是,2億美元是4%。我們有相當多的舉措,希望在我們已經交付的2億美元之外,繼續——繼續推動落地。現在就把這些加到2027年及以後的規劃裡還太早。而且我們會有充足的時間來討論。但我認為你提出的問題方向是對的。我的意思是,我們還預期什麼?還有更多。我的意思是,這點毫無疑問。

  • Jack Meehan - Equity Analyst

    Jack Meehan - Equity Analyst

  • Great. And then Amol, one just phasing question for you. So when I look at the acquired revenue, you did $817 million this quarter. You're guiding to $895 million next quarter. How much of that is like the historical seasonality of these BD businesses? Obviously, like they had a different fiscal year-end than water. So I'm wondering whether the seasonality should look similar in Waters hands like just in terms of how the sales force is being incentivized?

    很好。然後Amol,我有一個關於時點分布(phasing)的問題。所以當我看你們收購而來的營收時,你們本季做了8.17億美元。你們指引下季為8.95億美元。其中有多少是這些BD業務歷史上的季節性所致?顯然,它們的財年結束時間和Waters不同。所以我想知道,在Waters接手後,季節性是否會看起來相似——就銷售團隊的激勵方式而言?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yes. I mean pretty much so, right? I mean, just keep in mind, our transformation is turning ahead of plan, and that could normalize some of that seasonality. But other than that, I mean, there's about consistent with how the businesses have been performing in the last two or three years.

    是的。我的意思是,基本上是這樣,對吧?只是請記住,我們的轉型進度超前於計畫,這可能會讓部分季節性趨於正常化。除此之外,我的意思是,整體大致與這些業務在過去兩三年的表現一致。

  • Operator

    Operator

  • Dan Leonard, RBC Capital Markets.

    Dan Leonard,RBC資本市場。

  • Daniel Leonard - Analyst

    Daniel Leonard - Analyst

  • At a risk of being a bit redundant here, I just want to talk a bit more about the sustainability of the improved trajectory in BD and reconcile some of the math. So Udit I hear you that the exit is greater than 6% growth, but you have a negative 10% comp in Q4. And that $895 Q3 guide, that does assume a deceleration in growth compared to your trend. So sort of similar to Jack, I'm not sure if there's a fiscal versus calendar dynamic, but just hoping you could reconcile some of that math?

    冒著有點重複的風險,我想再多談一點BD改善後成長軌跡的可持續性,並把一些數字對起來。所以Udit,我聽到你說退出(exit)時的成長率高於6%,但你們在Q4有-10%的可比基期(comp)。而你們Q3指引的8.95億美元,確實假設相較於你們的趨勢成長會放緩。所以有點像Jack的問題,我不確定這是否是財年與曆年之間的動態差異,但希望你能把這些數字邏輯對一下?

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • Yes, there is some amount of that, right? In the sense, if you specifically, if you look at Q3 being year-end for BD, there was about $20 million of trade inventory build in Q3 that unwound in Q4, and that creates a 3% or so growth headwind in Q3 and a 3% tailwind in Q4. Yes, we don't plan to do that here.

    是的,確實有一部分是這個因素,對吧?也就是說,如果你特別看,Q3作為BD的年末,Q3大約有2,000萬美元的通路庫存(trade inventory)建立,到了Q4回轉(unwind),這在Q3造成約3%的成長逆風,在Q4則形成約3%的順風。是的,我們不打算在這裡這麼做。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Yes. And on the 6% growth, right, look, I mean Q3 had a higher base, Q4 had a lower base. But I mean, the better way to think about it is the second half of the year, right? First half, we -- basically, the first quarter of full ownership, we finished at 4%. And when you look at the second half, we're accelerating versus the first half of the calendar year, right?

    是的。至於6%的成長,對吧,你看,Q3的基期較高,Q4的基期較低。但更好的思考方式是看下半年,對吧?上半年——基本上,在完全持有後的第一個季度,我們以4%收官。而當你看下半年時,相較於曆年上半年,我們是在加速的,對吧?

  • So the business is accelerating as you go from the first half to the second half. I mean the quarterization guys is very difficult to predict in a newly acquired business, and this is something that I've seen in the past with the Sigma acquisition as well. We feel very good about the momentum that we're seeing in the business and the 6%, it gives you a very good starting point as we enter 2027.

    所以,從上半年到下半年,業務是在加速的。我的意思是,對於一個新收購的業務,要按季度拆分(quarterization)去預測非常困難,這也是我過去在Sigma收購案中見過的情況。我們對目前在業務中看到的動能感到非常有信心,而6%也為我們進入2027年提供了一個非常好的起點。

  • Amol Chaubal - Chief Financial Officer, Senior Vice President

    Amol Chaubal - Chief Financial Officer, Senior Vice President

  • And also China is 6% already for both the businesses. And China started to come into baseline so in Q4 --

    另外,中國對兩個業務來說都已經是6%。而中國在Q4開始回到基準線,所以在Q4——

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • For both business.

    對兩個業務都是。

  • Daniel Leonard - Analyst

    Daniel Leonard - Analyst

  • Understood. And then as a follow-up, I was hoping you could share more of your early insight into the diagnostics replacement opportunity. with the FXI, would you compare it to the alliance I asked but just given that the markets are different between diagnostics and pharma, I was hoping to get some of your early learnings.

    了解。接著追問一下,我希望你能分享更多你們對診斷替換機會的早期洞見。就FXI而言,你會把它和我問到的Alliance iS做比較嗎?只是考量到診斷與製藥的市場不同,我希望聽聽你們的一些早期學習。

  • Udit Batra - President, Chief Executive Officer, Director

    Udit Batra - President, Chief Executive Officer, Director

  • Some similarity and some differences. Look, I mean, it's a replacement business regardless. That's the similarity. It's 12,000 instruments that are ripe for replacement. 4500 in the US alone, excellent uptake of FXI, -- it's a differentiated product with a clear value proposition and customers are seeing the benefit wherever we've launched it already.

    有一些相似之處,也有一些不同。你看,我的意思是,不管怎樣它都是替換型業務。這就是相似之處。有12,000台儀器已經到了適合替換的時點,光是在美國就有4,500台;FXI的採用情況非常好——它是一個差異化產品,價值主張清晰,而且在我們已經推出的地方,客戶都看到了效益。

  • So remember, whenever we talk about replacement cycles, it's not just the math, it's also the value proposition of the new product, right? So the reason we're excited about the replacement cycle that we see with FXI as well as with A7. There's an in stories that is right for replacement. But these are fantastic new products that are meeting clear, clear unmet needs.

    所以請記住,當我們談替換週期時,不只是數學計算,還包括新產品的價值主張,對吧?所以我們之所以對FXI以及A7所帶來的替換週期感到興奮,是因為——有一個儀器存量(installed base)確實到了該替換的時點。但這些都是非常出色的新產品,正在滿足非常、非常明確的未被滿足需求。

  • So the similarity to Alliance iS is it's a differentiated product with an incumbent installed base that we know, we know the segmentation and the installed base replacement will go exactly according to what happened with Alliance iS, it's a multiyear process.

    所以與Alliance iS的相似之處在於:它是一個差異化產品,且有我們熟悉的既有裝機基礎(incumbent installed base);我們了解分層(segmentation)與裝機基礎,而裝機替換將會完全按照Alliance iS當時的情況發展——這是一個跨多年的過程。

  • The difference is that it's a Reagent rental model, right, which in itself is actually an advantage because the -- it allows you to take advantage not just of the replacement opportunity but also of delinquent accounts. Where you can go into the customer and say, hey, owe me XYZ from the past, let's accelerate your replacement with the FXI BACTEC, right? So the reagent rental model has several advantages, one of which is the lack of compliance that we see from the past, and that presents an opportunity.

    不同之處在於它是試劑租賃(reagent rental)模式,對吧?而這本身其實是一個優勢,因為——它讓你不僅能把握替換機會,也能處理逾期帳款(delinquent accounts)。你可以去找客戶說:嘿,你過去欠我XYZ,我們就用FXI BACTEC來加速你的替換,好嗎?所以試劑租賃模式有幾個優勢,其中之一是我們看到過去存在的合規性不足,而這帶來了機會。

  • And the second, it shows up as recurring revenue, where you can add on pricing in a sustainable way. So it's similar and different similar in the sense that it's a replacement cycle, new products, different in the sense that it's actually going to be a sustainable recurring revenue that you will see over a benefit of over many, many years.

    第二,它會以經常性收入(recurring revenue)的形式呈現,你可以用可持續的方式加入定價(pricing)。所以它既相似也不同:相似在於它是一個替換週期、有新產品;不同在於它實際上會是可持續的經常性收入,你將在很多很多年中看到其帶來的效益。

  • Operator

    Operator

  • This concludes the Q&A portion of the call. I will now hand it back to Caspar.

    問答環節到此結束。我現在把電話交回給Caspar。

  • Caspar Tudor - Head - Investor Relations

    Caspar Tudor - Head - Investor Relations

  • Thank you, Leila. This concludes our call. We look forward to connecting with many of you at upcoming events and conferences.

    謝謝你,Leila。本次電話會議到此結束。我們期待在接下來的活動與會議上與各位中的許多人交流。